Drug · DIN 02509733
INCRELEX
MULTIDOSE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 11, 2026; first marketed March 1, 2021.
- Drug Identification Number (DIN)
- 02509733
- Company (DIN owner)
- Esteve Pharmaceuticals S.A.Barcelona, Barcelona, Spain
- Schedule
- Schedule d; Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Mecasermin H01AC03
- Class
- Human
- Record last updated
- July 31, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| MECASERMIN | 10 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 8, 2026: NOC 37503New Drug Submission (NDS) · Administrative – Changes in product ownership
- October 14, 2021: NOC 26901Supplement to a New Drug Submission (SNDS) · Labelling updates
- December 17, 2020: NOC 24820New Drug Submission (NDS)